Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel
Inspira Technologies (Nasdaq: IINN) announced its participation at the annual iECOs Conference in Herzliya, Israel, on June 18, 2024.
The company will showcase the INSPIRA™ ART100 System, which recently received 510(k) clearance from the U.S. FDA and is pending approval from Israel's AMAR.
Inspira's R&D team will be available to discuss their advanced life support solutions and other technologies in development.
For meetings, attendees can contact the company via info@inspira02.com.
- INSPIRA™ ART100 System received 510(k) clearance from the U.S. FDA.
- Pending approval from AMAR, Israel's Ministry of Health.
- Showcasing advanced life support solutions at a major international conference.
- Direct engagement opportunities with R&D team for potential investors and partners.
- Approval from AMAR is still pending, creating uncertainty.
- No financial data or revenue projections provided in the announcement.
- The PR lacks information on commercial launch timelines or market strategy.
RA'ANANA,
![Inspira Technologies Logo Inspira Technologies Logo](https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg)
The Company will present the INSPIRA™ ART100 System, recently 510(k)
About iECOs
iECOs, known as the Israeli ECMO Society, is a medical organization for medical professionals in the fields of ICU medicine including pediatrics, cardiac medicine and surgery, heart-lung specialists, emergency medicine and heart failure to share knowledge and professional experiences, to improve and promote extracorporeal oxygenation education and medical practice.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology company in the life support arena. The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, shall include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that requires intubation and medically induced coma.
The Company received FDA 510(k) clearance for its INSPIRA ART100, a Cardiopulmonary Bypass System.
The Company's other products, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, have not yet been tested or used in humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-introduces-advanced-life-support-solutions-to-key-international-leaders-at-the-annual-iecos-conference-in-israel-302174164.html
SOURCE Inspira Technologies
FAQ
What did Inspira Technologies announce on June 17, 2024?
What is the INSPIRA™ ART100 System?
When and where will Inspira Technologies present its new system?
How can attendees schedule a meeting with Inspira Technologies?